Composition Wealth LLC increased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 7.5% in the third quarter, Holdings Channel.com reports. The firm owned 48,831 shares of the biopharmaceutical company’s stock after buying an additional 3,401 shares during the quarter. Composition Wealth LLC’s holdings in Gilead Sciences were worth $7,278,000 at the end of the most recent reporting period.
Several other large investors have also recently bought and sold shares of GILD. Bank of Nova Scotia bought a new stake in Gilead Sciences in the second quarter valued at about $100,056,000. OMERS ADMINISTRATION Corp acquired a new position in Gilead Sciences in the second quarter valued at about $55,754,000. Groupe la Francaise boosted its holdings in Gilead Sciences by 30.9% during the second quarter. Groupe la Francaise now owns 49,627 shares of the biopharmaceutical company’s stock worth $6,270,000 after buying an additional 11,712 shares during the last quarter. Baird Financial Group Inc. boosted its holdings in Gilead Sciences by 3.6% during the second quarter. Baird Financial Group Inc. now owns 292,295 shares of the biopharmaceutical company’s stock worth $36,929,000 after buying an additional 10,206 shares during the last quarter. Finally, Headlands Technologies LLC bought a new position in Gilead Sciences during the second quarter worth about $6,251,000. 83.67% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
A number of analysts have recently commented on the company. Citigroup upped their price target on Gilead Sciences from $165.00 to $188.00 and gave the company a “buy” rating in a research note on Friday, October 30th. HSBC lifted their price objective on shares of Gilead Sciences from $155.00 to $175.00 and gave the stock a “buy” rating in a research note on Thursday, September 10th. Morgan Stanley boosted their price objective on shares of Gilead Sciences from $163.00 to $183.00 and gave the company an “overweight” rating in a report on Friday, October 30th. Cantor Fitzgerald upped their target price on shares of Gilead Sciences from $155.00 to $175.00 and gave the company an “overweight” rating in a research note on Friday, October 30th. Finally, BMO Capital Markets reiterated an “outperform” rating and issued a $184.00 target price on shares of Gilead Sciences in a report on Friday, October 30th. Twenty-three investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $171.63.
View Our Latest Report on Gilead Sciences
Insider Transactions at Gilead Sciences
In other Gilead Sciences news, CEO Daniel O’Day sold 9,810 shares of the business’s stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $175.17, for a total value of $1,718,417.70. Following the completion of the sale, the chief executive officer owned 551,683 shares of the company’s stock, valued at $96,638,311.11. The trade was a 1.75% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Keeley Cain Wettan sold 3,399 shares of the firm’s stock in a transaction on Friday, November 6th. The stock was sold at an average price of $164.11, for a total value of $557,809.89. Following the transaction, the executive vice president owned 5,360 shares in the company, valued at approximately $879,629.60. This trade represents a 38.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 237,709 shares of company stock valued at $39,799,137. 0.30% of the stock is currently owned by company insiders.
Trending Headlines about Gilead Sciences
Investors following GILD have been watching these headlines:
- Positive Sentiment: Gilead signed royalty-free licensing agreements with three generic manufacturers to enable potential future access to its experimental Ebola antiviral obeldesivir in 127 countries, subject to regulatory authorization. This supports the drug’s reach, though near-term revenue is unlikely. Article: Gilead partners with generic manufacturers
- Neutral Sentiment: Gilead completed a new research center in Foster City, adding specialized laboratory capacity that may support research over time, but carries no stated immediate financial impact. Article: Research center completion
- Negative Sentiment: CFO Andrew Dickinson sold 3,000 shares, and insider Johanna Mercier sold 28,000 shares. Both transactions were made under pre-arranged Rule 10b5-1 plans, which makes them less informative as signals about near-term company prospects, but insider sales can still add modest pressure to sentiment. Article: CFO share sale
Gilead Sciences Trading Down 0.8%
Shares of NASDAQ:GILD opened at $168.98 on Thursday. The company’s 50-day moving average price is $156.37 and its two-hundred day moving average price is $142.23. Gilead Sciences, Inc. has a one year low of $116.88 and a one year high of $176.58. The company has a debt-to-equity ratio of 1.84, a current ratio of 1.38 and a quick ratio of 1.22. The stock has a market capitalization of $209.59 billion, a PE ratio of -53.47 and a beta of 0.35.
Gilead Sciences (NASDAQ:GILD – Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.19 by $0.36. The firm had revenue of $8.30 billion for the quarter, compared to analyst estimates of $7.81 billion. Gilead Sciences had a negative net margin of 12.47% and a negative return on equity of 1.85%. The company’s quarterly revenue was up 6.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.47 earnings per share. On average, equities analysts forecast that Gilead Sciences, Inc. will post -0.97 EPS for the current fiscal year.
Gilead Sciences Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Wednesday, December 30th. Stockholders of record on Tuesday, December 15th will be paid a dividend of $0.82 per share. The ex-dividend date is Tuesday, December 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 1.9%. Gilead Sciences’s dividend payout ratio (DPR) is -103.80%.
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C. Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.
Further Reading
- Five stocks we like better than Gilead Sciences
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD – Free Report).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
